Results 201 to 210 of about 250,267 (258)

Circulating tumor DNA-based minimal residual disease-guided adjuvant therapy in solid tumors: Current evidence, clinical trial frameworks, and future directions. [PDF]

Chin J Cancer Res
Ma M, Xia B, Xu Q, Chu J, Li S, Liu L.
europepmc   +1 more source

A nationwide student survey on biochemistry learning resources in Italy

FEBS Open Bio, EarlyView.
We conducted a survey among Italian university students to investigate their preferred study materials for biochemistry. We then analyzed the collected data to identify these materials. This information may be valuable to the Biochemistry educational community. The graphical abstract was created with Claude (Opus 5.5; Anthropic, 2026).
Anna Marabotti, Ivano Eberini, Maria Luisa Genova, Francesca Mensitieri, Francesco Malatesta   +4 more
wiley   +1 more source

Diagnostic Accuracy and Prognostic Value of Flow Cytometry Versus PCR-Based Minimal Residual Disease Assessment in Leukemia: A Systematic Review and Meta Analysis. [PDF]

Cureus
Alalwy A, Alshreef BS, Semoud I, Ahmed B, Alyousfi SA, Sayed MM, Alshammari TR, Alaslani TA, Alanazi AF, Alaufi SA, Metwaly AS.   +10 more
europepmc   +1 more source

Hydrogel platforms for 3D cardiac tissue engineering and fibrotic disease modelling

FEBS Open Bio, EarlyView.
Hydrogel‐based cardiac tissue models are advancing our understanding of heart health and disease. By incorporating electrical conductivity, aligned structures, and tunable mechanical properties, these platforms better replicate the complex environment of native heart tissue.
Harrison Porritt, Annika Winbo, Jenny Malmström   +2 more
wiley   +1 more source

Optimal minimal residual disease threshold in pediatric acute myeloid leukemia: A retrospective cohort study based on the TARGET database. [PDF]

PLoS Med
Liao XY, Zheng H, Fang JP, Zhou DH, Qiu KY.   +4 more
europepmc   +1 more source

Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma. [PDF]

Target Oncol
Gan X, Li L, Zhang L, Zheng Y, Niu T, Yu Z.   +5 more
europepmc   +1 more source

Mass spectrometry-based proteomics and metabolomics in multiple myeloma: a systematic review of prognostic biomarkers and minimal residual disease monitoring. [PDF]

Front Med (Lausanne)
Moursy N, Siraj H, Nasir Z, Tanweer A, Sajid MR.   +4 more
europepmc   +1 more source

The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC). [PDF]

Cancers (Basel)
Gillis R, Zahavi T, Peled N, Yaacov A, Afifi B, Salim J, Basheer R, Asna N, Makori A, Peer M, Gershman E, Manaster Y, Moreh Rahav O, Dudnik E.   +13 more
europepmc   +1 more source

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group. [PDF]

Clin Hematol Int
Chen W, Cai Z, Chim CS, Chng WJ, Du J, Fu C, Gao W, Hanamura I, Hou J, Huang JS, Ishida T, Li C, Liu A, Ptushkin V, Takezako N, Wong RSM, Yoon DH.   +16 more
europepmc   +1 more source

Circulating Tumor DNA-Based Assessment of Minimal Residual Disease in Colorectal Cancer: Prognostic and Predictive Implications. [PDF]

Cancers (Basel)
Ozluk AA, Colley W, Arik ZB, Kostek O, Sunkari A, Malla M, Akce M.   +6 more
europepmc   +1 more source